Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ: NEO )

15.42 +1.64 (+11.90%)
Streaming Delayed Price Updated: 9:41 AM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
NEO Stock Earnings: NeoGenomics Beats EPS, Beats Revenue for Q1 2024
NEO stock results show that NeoGenomics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
NeoGenomics Reports First Quarter 2024 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Announces Senior Leadership Promotions
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
From NeoGenomics, Inc.
Via Business Wire
What 6 Analyst Ratings Have To Say About NeoGenomics
Via Benzinga
Evaluating NeoGenomics: Insights From 4 Financial Analysts
Via Benzinga
Recap: NeoGenomics Q4 Earnings
Via Benzinga
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
From NeoGenomics, Inc.
Via Business Wire
Earnings Scheduled For March 15, 2024
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million. 
Via Benzinga
NeoGenomics's Earnings Outlook
Via Benzinga
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
From NeoGenomics, Inc.
Via Business Wire
Goldman Sachs Maintains Buy Rating for NeoGenomics: Here's What You Need To Know
Via Benzinga
NeoGenomics Stock Surged But Technicals Point To A Pullback
NeoGenomics stock price popped sharply this week after the company published strong financial results. It soared to a high of $16.50, its highest point since December 29th. It has soared by more than... 
Via Talk Markets
Why Is Cancer Genetics Test-Focused NeoGenomics Stock Trading Higher Today?
NeoGenomics shines in Q4 2023 with an EPS turnaround to $0.03, beating estimates. Sales reach $155.55 million. CEO Chris Smith anticipates strong growth, guiding a positive fiscal 2024 outlook with an... 
Via Benzinga
Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
Why NeoGenomics Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of NeoGenomics, Inc. (NASDAQ: NEO) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY24 adjusted EPS... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Wednesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
From NeoGenomics, Inc.
Via Business Wire
Earnings Scheduled For February 20, 2024
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
From NeoGenomics, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
From FN Media Group LLC
Via GlobeNewswire
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
From NeoGenomics, Inc.
Via Business Wire
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
The company must pay $57 million in damages, but that's far less than expected. 
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Bull of the Day - NeoGenomics
But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context. 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
From The Rosen Law Firm, P.A.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.